- PARADIGM4TB enrolled 401 adults with lung TB susceptible to rifampicin.
- Researchers selected two 16-week combinations for the next phase of evaluation.
- The study does not establish a new standard of care or show that other patient groups could use the same regimens.
Inside this story 2 perspectives
Ten experimental drug combinations went into the first stage of an international tuberculosis trial. Two are going forward. The results, released during the Union World Conference on Lung Health in Rio de Janeiro, move researchers closer to asking a question that matters outside the laboratory: how short can a course be and still leave a patient well months after the last dose?
The two combinations were tested over 16 weeks. One includes an investigational drug called ganfeborole and the other a compound called BTZ-043. Their selection, reported on 19 November, is a decision about where to invest the next round of research. The trial has not produced a new prescription for people being treated for TB.
Why keep checking after the medicine stops?
The PARADIGM4TB study enrolled 401 adults at 14 sites across five countries. All had TB affecting the lungs that was susceptible to rifampicin, an established TB medicine. Researchers tested several combinations within one study. That let the teams compare promising candidates against a common standard, rather than setting up a separate trial for every option.
They looked at how quickly bacteria cleared from samples patients coughed up during the first 12 weeks. They also looked at whether treatment had failed or the disease had returned by week 48. The two measures answer different questions. An encouraging early response can help researchers choose which combinations deserve a closer look. A patient also needs to know how well that response holds up after treatment.
Safety mattered in that choice. The investigators reported a signal of excess liver toxicity in a different combination that also contained BTZ-043. It would be misleading to attach that finding to every use of the compound. It does explain why researchers have to examine the individual combinations and their side effects alongside how well they control the infection.
The value of getting weeks back
For a commuter making return trips to a clinic, a shorter course could mean fewer weeks of fitting treatment around work and family life. How much difference that would make depends partly on the way clinics deliver care. The trial did not measure saved wages or transport costs. Nor do its results establish what would work for children, for people with TB outside the lungs or for those whose infection is resistant to rifampicin.
The next stage will explore how far the selected treatments can be shortened while preserving their effect. Larger confirmatory studies would still be needed before these experimental regimens could become options for patients. In a week of conference announcements, the useful news is quite precise. Researchers have narrowed ten possibilities to two and identified the later outcome against which a shorter course has to earn its place.



